Get Started today or visit our FAQ page for more information
Ricks, chair and CEO of Eli Lilly, current utilization of GLP-1s remains low relative to the population that could benefit, citing fewer than 1 in 10 people who could benefit from a GLP-1 are taking one, held back by access, stigma, perceived complexity or the belief that their condition isn't serious enough for treatment. 2 We believe Foundayo can help level the playing field for those living with obesity or who are overweight and living with weight-related complications, Ricks said
Just as healthy food choices may increase GLP-1 levels, so can exercise
These types of data and the difficulty to manufacture a peptide like GLP-1, raise the barriers to entry for the duopolist market leaders
12 However, the benefits of liraglutide in reducing weight, hepatic steatosis, and hepatocellular apoptosis in obese adults with MASLD were not sustained upon discontinuation, especially when compared to lifestyle modifications (NCT02654665)